Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists
Authors:
- Trevor A. HowlettTHTrevor A. Howlett
- Peter J. TrainerPTPeter J. Trainer
- UK Acromegaly Register Study Group (UKAR-3)U(UK Acromegaly Register Study Group (UKAR-3)
Open Access
- 11 April 2013
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 79 (5) , 689-699
Abstract
Objective: We investigated the control of GH and IGF1 in acromegaly in routine clinical practice in the UK on and off medical treatment.Design: The UK Acromegaly Register collected routine biochemical and clinical data on patients with acromegaly from 31 UK centres with GH data covering >30y.Patients: We identified 2572 patients. Somatostatin analogues (SMS) were used in 40·6% and dopamine agonists (DA) in 41·4%.Measurements: We identified 29,181 GH records linked to data on IGF1, surgery, radiotherapy and medical treatment and derived data on 9900 distinct Periods of Care including 4206 courses of medical treatment. We considered GH controlled when ≤2 μg/l.Results: Control of GH and IGF1 improved over time, particularly on medical treatment. Control on medical treatment was better after prior surgery and/or radiotherapy. On long‐term SMS, GH was controlled in 75%, IGF1 in 69% and both in 55%; on long‐term DA, GH control was similar but IGF1 worse (77%/55%/45%). Responses to long‐term treatment with octreotide LAR and lanreotide autogel were broadly similar, but we noted a failure to escalate SMS to maximal effective dose. Increasing precourse GH levels were associated with a decreasing proportion who achieved control, despite greater suppression from baseline.Conclusions: Control of acromegaly in the UK is improving, but ‘safe’ GH levels are still only achieved in 75% on long‐term medical treatment, with GH and IGF1 both normalized in no more than 55% on SMS and 36% on cabergoline. It remains unclear whether the control of GH, but not IGF1, observed in many patients is sufficient to restore long‐term morbidity and mortality to normal.Keywords
This publication has 21 references indexed in Scilit:
- Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly RegisterEuropean Journal of Endocrinology, 2013
- Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA)Pituitary, 2012
- Clinical, quality of life, and economic value of acromegaly disease controlPituitary, 2011
- A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegalyEuropean Journal of Endocrinology, 2008
- AcroBel – the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjectsEuropean Journal of Endocrinology, 2007
- Wide variation in surgical outcomes for acromegaly in the UKClinical Endocrinology, 2007
- Criteria for Cure of Acromegaly: A Consensus StatementThe Journal of Clinical Endocrinology & Metabolism, 2000
- Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort StudyThe Journal of Clinical Endocrinology & Metabolism, 1998
- Cabergoline in the Treatment of Acromegaly: A Study in 64 PatientsThe Journal of Clinical Endocrinology & Metabolism, 1998
- Long-term treatment of acromegaly with bromocriptine.BMJ, 1977